TICKER INTELLIGENCE
NYSE/NASDAQ: CTVA
Corteva Agriscience is a publicly traded company in the Agriculture sector. This company operates across Agriculture and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 3 active Congressional signals mentioning Corteva Agriscience, including 3 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
Corteva Agriscience ($CTVA) is currently facing 3 active congressional signals tracked by HillSignal. With 0 bullish, 2 neutral, and 1 bearish signals, the average legislative impact score is 3.0/10. Key sectors affected include Agriculture and Technology. Recent major catalysts include To amend the Food Security Act of 1985 to repeal certain provisions relating to the acceptance and use of contributions for public-private partnerships, and for other purposes. and DALCI Act. Below is the complete tracker of government activity affecting Corteva Agriscience’s market performance.
3
Total Signals
3.0/10
Avg Impact
0
Bullish Signals
1
Bearish Signals
The AFIDA Improvements Act of 2025 (S.1969) is a procedural bill tightening foreign ownership reporting for U.S. agricultural land. It authorizes no spending and is in early committee stage. The bill has zero near-term market impact for any publicly traded company.
The DALCI Act (HR7330) is an early-stage bill authorizing $25M over five years for climate-smart agriculture and ecological restoration in the Driftless Area. Referred to committee with a single cosponsor, it faces a long legislative path and requires separate appropriations. Near-zero market impact.
HR773, introduced by Rep. Hageman (R-WY), repeals the SUSTAINS Act's public-private partnership provisions at NRCS, removing a co-funding mechanism for agricultural sustainability programs. This eliminates a demand driver for precision agriculture and conservation products from companies like Corteva ($CTVA) and Deere ($DE), as farmer adoption incentives are reduced. The bill is in early committee stage with no counterpart in the Senate, lowering near-term passage probability.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →